RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome
Jonathan G. Pol, Andrea Checcoli, Manuela Lizarralde-Guerrero, Guido Kroemer · 2024
Read RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome by Jonathan G. Pol, Andrea Checcoli, Manuela Lizarralde-Guerrero, Guido Kroemer (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11540075.txt.
Description
Jonathan Pol and co-authors summarize a new cancer drug angle in a 2024 commentary. The target is RIPK1, a protein that holds back apoptosis, necroptosis, and an inflammatory signaling path. A recent paper in Immunity describes a small molecule that forces cells to destroy RIPK1. In preclinical tests, blocking the protein this way strengthened other treatments. Radiation worked better with it. So did immunotherapy using PD-1 blockade, and combined radioimmunotherapy with CTLA-4 blockade. The authors present RIPK1 destruction as a way to make standard cancer treatments bite harder.
Catalog record
| CREATOR | Jonathan G. Pol, Andrea Checcoli, Manuela Lizarralde-Guerrero, Guido Kroemer |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 7 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |